

AVELLINO CoV2 CORONAVIRUS TEST

AvellinoCoV2

Development

The COVID-19 outbreak has been fast and severe, first affecting the Avellino teams and facilities in China and South Korea. While infectious disease diagnostics has never been a company focus, Avellino management leveraged our genetic testing capabilities to help our employees in Asia and then realized that our potential to impact public health was much larger than that.

Recognizing that Avellino could help with Coronavirus detection, the company moved quickly to contact and work with the CDC and FDA to find a proper way to diagnose the active virus, even in people who don't yet show symptoms.

The FDA-authorized AvellinoCoV2 Coronavirus diagnostic test (patent pending) identifies the two genetic targets that test the SARS-CoV-2 virus expression. Original CDC protocol specified that Coronavirus testing required three specific genetic targets, but Avellino confirmed through its validation process that only two of these parts work in identifying COVID-19. Shortly after Avellino notified the CDC of its discovery, the CDC updated its own protocol.

AvellinoCoV2 Test Features

- **ASYMPTOMATIC DETECTION**
 - The AvellinoCoV2 test quickly and accurately identifies the active virus in individuals infected with the COVID-19 virus both during the incubation period *before symptoms appear*—while the host is unknowingly infecting others – as well as after symptoms manifest
- **HIGH ACCURACY**
 - Proprietary RNA N-gene targeting method is accurate even as the virus evolves over time
- **ULTRA-RAPID TURNAROUND** – Same-day results
- **NON-INVASIVE SAMPLE COLLECTION** – Simple swab of throat and nose

The Public Health Benefit

- **ACCURATE DIAGNOSTIC TOOL**
 - By knowing which patients are infected with COVID-19 before symptoms present, physicians and public health officials can reliably advise seemingly healthy patients to properly mitigate against the spread of the disease
 - This provides physicians and governments with a significant new level of diagnostic insight to help proactively slow the spread of Coronavirus
 - With organization-wide proactive testing, public and private institutions could potentially be able to function with confidence that workers are uninfected. This includes vital service providers such as:
**Hospitals • Healthcare Workers • First Responders • Businesses • Schools
Government • Military • Aviation • Warehouses • Transportation • and More**

